Source:http://linkedlifedata.com/resource/pubmed/id/16497565
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0008565,
umls-concept:C0017431,
umls-concept:C0028978,
umls-concept:C0032105,
umls-concept:C0080103,
umls-concept:C0086418,
umls-concept:C0185125,
umls-concept:C0201734,
umls-concept:C0332324,
umls-concept:C0680730,
umls-concept:C0870883,
umls-concept:C1148554,
umls-concept:C1332828,
umls-concept:C1542147
|
pubmed:issue |
2
|
pubmed:dateCreated |
2006-3-7
|
pubmed:abstractText |
A simple and sensitive column-switching high-performance liquid chromatographic method was developed for the simultaneous determination of omeprazole and its two main metabolites, 5-hydroxyomeprazole and omeprazole sulfone, in human plasma. Omeprazole, its two metabolites and lansoprazol as an internal standard were extracted from 1 ml of alkalinized plasma sample using diethyl ether-dichloromethane (45:55, v/v). The extract was injected into a column I (TSK-PW precolumn, 10 microm, 35 mm x 4.6 mm i.d.) for clean-up and column II (Inertsil ODS-80A column, 5 microm, 150 mm x 4.6mm i.d.) for separation. The mobile phase consisted of phosphate buffer-acetonitrile (92:8 v/v, pH 7.0) for clean-up and phosphate buffer-acetonitrile-methanol (65:30:5 v/v/v, pH 6.5) for separation, respectively. The peak was detected with an ultraviolet detector set at a wavelength of 302 nm, and total time for chromatographic separation was approximately 25 min. The validated concentration ranges of this method were 3-2000 ng/ml for omeprazole, 3-50 ng/ml for 5-hydroxyomeprazole and 3-1000 ng/ml for omeprazole sulfone. Mean recoveries were 84.3% for omeprazole, 64.3% for 5-hydroxyomeprazole and 86.1% for omeprazole sulfone. Intra- and inter-day coefficient variations were less than 5.1 and 6.6% for omeprazole, 4.6 and 5.0% for 5-hydroxyomeprazole and 4.6 and 4.9% for omeprazole sulfone at the different concentrations. The limits of quantification were 3 ng/ml for omeprazole and its metabolites. This method was suitable for use in pharmacokinetic studies in human volunteers, and provides a useful tool for measuring CYP2C19 activity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1570-0232
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
7
|
pubmed:volume |
832
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
241-8
|
pubmed:meshHeading |
pubmed-meshheading:16497565-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:16497565-Chromatography, High Pressure Liquid,
pubmed-meshheading:16497565-Female,
pubmed-meshheading:16497565-Genotype,
pubmed-meshheading:16497565-Humans,
pubmed-meshheading:16497565-Hydrogen-Ion Concentration,
pubmed-meshheading:16497565-Male,
pubmed-meshheading:16497565-Mixed Function Oxygenases,
pubmed-meshheading:16497565-Omeprazole,
pubmed-meshheading:16497565-Reproducibility of Results,
pubmed-meshheading:16497565-Sensitivity and Specificity,
pubmed-meshheading:16497565-Spectrophotometry, Ultraviolet
|
pubmed:year |
2006
|
pubmed:articleTitle |
Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes.
|
pubmed:affiliation |
Department of Clinical Pharmacology, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan.
|
pubmed:publicationType |
Journal Article,
Validation Studies
|